GlassScriptPhysician profile
Farouk Al Chami
NPI 1831708551
$744.23
in general payments reported to CMS, 2019-2025
13 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $225 · 2023: $75.08 · 2024: $277 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $283.45 | 2021-2025 | Breztri, Airsupra |
| Regeneron Healthcare Solutions, INC. | $100.71 | 2024-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $98.31 | 2024 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $66.01 | 2023-2024 | Aralast |
| Verona Pharma, INC. | $28.18 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $26.06 | 2025 | Trelegy Ellipta |
| Genzyme Corporation | $23.89 | 2024 | |
| Vifor Pharma, INC. | $22.02 | 2024 | Zemaira |
| Merck Sharp & Dohme LLC | $21.47 | 2024 | Winrevair |
| Alexion Pharmaceuticals, INC. | $21.42 | 2025 | Ultomiris |
| Genentech USA, INC. | $20.68 | 2023 | Xolair |
| Boston Scientific Corporation | $16.21 | 2024 | |
| Philips North America LLC | $15.82 | 2024 | (Ak6) Vest Therapy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farouk Al Chami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.